Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding

GuoZhen Wang1, Alan R Fersht2

  • 1Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.

Insights

Mutant p53 proteins coaggregate with wild-type p53 and related proteins in cancer cells. This aggregation mechanism involves trapping rather than classical seeding, explaining p53

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Protein Biochemistry

Background:

  • Mutations in tumor suppressor protein p53 are common in cancer.
  • p53 family members (p63, p73) share structural similarities with p53.
  • Protein aggregation is implicated in various diseases, including cancer.

Purpose of the Study:

  • To investigate the aggregation behavior of mutant p53 proteins.
  • To determine if mutant p53 coaggregates with wild-type (WT) p53 and p53 family members.
  • To elucidate the mechanism of p53 aggregation in cancer.

Main Methods:

  • Utilized cancer cell lines expressing destabilized p53 mutants.
  • Analyzed co-aggregation of mutant p53 with WT p53, p63, and p73.
  • Compared aggregation kinetics of full-length tetrameric p53 with isolated core domains.

Main Results:

  • Destabilized mutant p53 proteins coaggregate with WT p53, p63, and p73 in cancer cell lines.
  • Mutant p53 primarily self-aggregates, with limited trapping of WT p53, p63, and p73.
  • p53 aggregation mechanism differs from classical seeding, involving sequential unfolding and cross-reaction.

Conclusions:

  • Mutant p53 aggregation in cancer is characterized by trapping and co-aggregation, not seeding.
  • The continuous production of mutant p53 in cancer cells can lead to gradual trapping of WT p53 and other proteins.
  • Understanding p53 aggregation mechanisms is crucial for developing targeted cancer therapies.